DeepSeq.AI
More data. Fewer surprises.
San Francisco, United States · Founded 2019
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- deepseq.ai
About
DeepSeq.AI is a privately held biotechnology company transforming AI-based protein drug discovery using hyperscaled experimental data. The company has built a Function-First platform that starts every drug design cycle with over one billion real protein interaction measurements — reaching trillions — enabling precise prediction of affinity, specificity, immunogenicity, pharmacokinetics, and manufacturability. This data-dense approach is designed to reduce costly late-stage failures and deliver better biologic drugs to patients faster. DeepSeq has partnered with Gilead Sciences, been selected as an Illumina Ventures Labs company, won ONO Pharmaceutical's 2024 Golden Ticket Competition, and received an NSF SBIR Phase I grant.
Summary
DeepSeq.AI is an Artificial Intelligence company based in San Francisco, United States, founded in 2019.
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...
Databricks is the pioneer of the data lakehouse, a unified platform for data science, machine lea...